Key facts
- BioProtect’s last known valuation is $200.0M (Jan 2026).
- It has raised $67.9M; the latest was Merger/Acquisition ($200.0M) in Jan 2026.
- Notable investors include KB Investment, Innovation Authority, Peregrine Ventures, Consensus Business Group, Vincent Tchenguiz — 21 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for BioProtect
- ·The full record, as it builds
Funding rounds
No funding rounds for BioProtect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioProtect
Developer of a pro-space balloon system designed to safely and temporarily separate the rectum during prostate cancer radiation therapy. The company's system acts as a spacer for the protection of healthy tissues in patients receiving radiotherapy for prostate cancer, enabling healthcare institutions to decrease the probability of serious and chronic radiation side effects while improving biochemical tumor control.
- Sector
- Healthcare
- HQ
- Tzur Yigal, Israel
- Founded
- 2004
- Employees
- 84
- Website
- bioprotect.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
BioProtect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioProtect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioProtect in its N-PORT filings yet. We sweep new filings monthly.